Trillium Therapeutics

Trillium is an immuno-oncology company developing innovative therapies for cancer treatment. The company's two clinical programs, TTI-622 and TTI-621, target CD47, a signal frequently used by cancer cells to evade the immune system. The company focuses on the immune system and its regulation, dedicating itself to the discovery and development of protein therapeutics such as monoclonal antibodies, secreted proteins, peptides, etc. It is involved in therapeutic areas including autoimmune diseases, cancer, necrotizing enterocolitis, and transplantation.